



33F Tower One, Ayala Triangle, Ayala Avenue
Makati City, 1226 Philippines
www.ayala.com.ph

June 4, 2019

Securities and Exchange Commission

PICC Complex, Roxas Boulevard, Pasay City

Attention: Director Vicente Graciano P. Felizmenio, Jr.
Director, Markets & Securities Regulation Department

Philippine Stock Exchange, Inc.

6/F PSE Tower
5th Avenue corner 28th Street
Bonifacio Global City, Taguig City

Attention: Ms. Janet A. Encarnacion
Head, Disclosure Department

Philippine Dealing and Exchange Corporation

37/F Tower 1, The Enterprise Center
6766 Ayala Ave cor. Paseo de Roxas, Makati City

Attention: Mr. Joseph B. Evangelista
Head, Issuer Compliance and Disclosure Department

Gentlemen:

In relation to our March 13, 2019 disclosure, please be informed that on June 3, 2019, Ayala Healthcare Holdings, Inc. ("AC Health") received the approval of the Philippine Competition Commission on its proposed increase in stake in the Generika group of companies. With this, AC Health will proceed with the closing of the increase in the stake from 50% to 52.5% as regards Actimed, Inc., Novellis Solutions, Inc. and Pharm Gen Ventures Corp. The increase in the stake in Erikagen, Inc. is still subject to certain conditions precedent.

Thank you.

Very truly yours,

A handwritten signature in black ink, appearing to read 'Jose Teodoro K. Limcaoco'.

JOSE TEODORO K. LIMCAOCO
Chief Finance Officer